ASX Announcement / Media Release

19 July 2022

Patient treated with the OncoSil™ Device in Spain proceed to successful resection of the tumour in the pancreas

Key Highlights

- ✓ **The Second patient commercially treated with the OncoSil™ device at The Hospital Universitario de Fuenlabrada in Madrid, Spain has undergone a successful resection of the primary tumour.**
- ✓ **OncoSil is continuing to work with a number of other institutions in Spain to enable increased patient access to treatments with the OncoSil™ device.**

Sydney, Australia – 19 July 2022: OncoSil Medical Ltd (ASX: OSL) (**OncoSil** or the **Company**), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC), is pleased to announce that the second patient treated at The Hospital Universitario de Fuenlabrada in Madrid, Spain has undergone a successful resection of the LAPC tumour.

This follows the announcement in April 2022 that OncoSil signed a commercial agreement with the Hospital for the treatment of patients with locally advanced pancreatic cancer worth €374k (A$553k).

The sales team in Spain is currently working with other trained hospitals to facilitate further agreements to enable greater patient access to the OncoSil™ device treatment in various regions throughout Spain.

The Head of Surgery at The Hospital Universitario de Fuenlabrada in Madrid, Professor. Dr. Fernando Pereira said:

"I am pleased that treatment with the OncoSil™ device has led to this excellent outcome for my patient and I look forward to further treating patients with the OncoSil™ device to improve both their quality of life and overall clinical outcomes."

OncoSil's CEO and Managing Director, Mr Nigel Lange said:

"We are encouraged by the resection undertaken on the patient who had received the OncoSil™ device for locally advanced pancreatic cancer (LAPC). In the PanCO trial, 23.8% of patients who were treated with the OncoSil™ device were successfully resected which has been demonstrated to improve patient outcomes from this insidious disease. We look forward to working with additional institutions in Spain and throughout Europe, in order to accelerate the use of the OncoSil™ device for the benefit of patients suffering from LAPC. In addition, we continue to investigate all relevant means to broaden the approved labelling for use."

—END—

ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL
Suite 503, Level 5, 15 Blue Street, North Sydney, NSW 2060 AUSTRALIA
TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9252 3988
WEB www.oncosil.com

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

Company	Company
Mr Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr Karl Pechmann CFO & Company Secretary E: karl.pechmann@oncosil.com T: +61 2 9223 3344

About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted six clinical studies with positive results on tolerability, safety and efficacy. CE Marking has been granted for the OncoSil™ device which can be marketed in the European Union and the United Kingdom. The OncoSil™ device has also been classified a Breakthrough Device in the European Union and the United Kingdom.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval.

In December 2018, the FDA granted Humanitarian Use Designation (HUD) for the OncoSil™ device for the treatment of unresectable bile duct cancer. In March 2020, the FDA granted Breakthrough Device Designation for the OncoSil™ for unresectable pancreatic cancer in conjunction with systemic chemotherapy.

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds $3b.

Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.